NRC - NRC Health

NRC Health provides the Frameworks human understanding platform, a healthcare experience measurement and analytics SaaS suite that collects and analyzes patient, employee, and physician sentiment data for hospitals and health systems. The business model is enterprise SaaS sold directly to large healthcare organizations, primarily through multi-year subscription contracts tied to bed count or organization size. Revenue is approximately $150M annually, with operations concentrated almost entirely in the United States healthcare market. The company serves roughly 75% of the top-ranked U.S. hospitals as measured by U.S. News & World Report rankings.

Past Year Trends

• Revenue declined 4% YoY to $137.4 million in FY2025 due to elevated customer attrition, continuing a multi-year contraction from $148.6 million in FY2023, compressing net income by roughly 20% over that span. (Bearish)
• NRC Health acquired NOBL Health in July 2024 for approximately $6 million and launched its Huey AI-enabled product suite in August 2024, combining patient rounding workflow tools with proprietary AI for consumer and employee experience measurement. (Bullish)
• Total Recurring Contract Value (TRCV) reversed direction and rose 13% year-over-year as of early 2026, projecting $152 million in renewable contract revenue over the next 12 months, signaling that the AI product refresh is beginning to stabilize the customer base. (Bullish)

Next Year Trends

• Revenue recovery in FY2026 is contingent on the 13% TRCV growth translating into recognized revenue; if attrition normalizes and renewal rates hold, management projects a return to top-line growth after two consecutive years of decline, but any renewal shortfall would extend the contraction. (Bullish)
• Top-10 customer concentration increased to 20% of FY2025 revenue (up from 15% in FY2023), meaning the loss or deferral of even one or two major health system contracts would have an outsized negative impact on revenue in the next renewal cycle. (Bearish)
• Adoption and upsell of the Huey AI suite within the existing customer base represents the primary organic growth lever for FY2026, with management explicitly attributing the TRCV turnaround to AI-enabled product innovation; slow enterprise adoption or competitive displacement by larger patient-experience platforms could limit upside. (Neutral)

Red Flags

No severe red flags identified as of August 2025.